ANRO ALTO NEUROSCIENCE INC revenue, earnings and financials
For the quarter ended June 30, 2026, ALTO NEUROSCIENCE INC reported revenue of n/a, net income of −$27.6M and diluted EPS of −$0.65; for the fiscal year ended December 2025 revenue was n/a.
ANRO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$66.4M, net income −$63.2M (margin n/a), EPS −$2.19
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$68.6M, net income −$61.4M (margin n/a), EPS −$2.50
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$37.8M, net income −$36.3M (margin n/a), EPS −$9.73
ANRO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$27.6M, EPS −$0.65
- Quarter ended Mar 31, 2026: revenue n/a, net income −$26.2M, EPS −$0.80
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$16.2M, EPS −$0.46
- Quarter ended Sep 30, 2025: revenue n/a, net income −$14.2M, EPS −$0.52
- Quarter ended Jun 30, 2025: revenue n/a, net income −$17.7M, EPS −$0.65
- Quarter ended Mar 31, 2025: revenue n/a, net income −$15.2M, EPS −$0.56
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$15.2M, EPS −$0.52
- Quarter ended Sep 30, 2024: revenue n/a, net income −$16.8M, EPS −$0.62
- Quarter ended Jun 30, 2024: revenue n/a, net income −$16.0M, EPS −$0.60
- Quarter ended Mar 31, 2024: revenue n/a, net income −$13.4M, EPS −$0.76
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$11.2M, EPS −$2.99
- Quarter ended Sep 30, 2023: revenue n/a, net income −$9.14M, EPS −$2.44
- Quarter ended Jun 30, 2023: revenue n/a, net income −$8.66M, EPS −$2.33
- Quarter ended Mar 31, 2023: revenue n/a, net income −$7.28M, EPS −$1.97
ANRO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$51.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$47.4M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$33.4M, share buybacks n/a
ANRO balance sheet
- Jun 30, 2026: cash $244M, total assets $254M, total liabilities $34.8M, shareholders' equity $219M, long-term debt $12.4M
- Mar 31, 2026: cash $264M, total assets $276M, total liabilities $32.9M, shareholders' equity $243M, long-term debt $13.9M
- Dec 31, 2025: cash $176M, total assets $185M, total liabilities $33.5M, shareholders' equity $151M, long-term debt $16.2M
- Sep 30, 2025: cash $138M, total assets $147M, total liabilities $35.4M, shareholders' equity $112M, long-term debt $20.3M
- Jun 30, 2025: cash $148M, total assets $158M, total liabilities $34.5M, shareholders' equity $123M, long-term debt $20.1M
- Mar 31, 2025: cash $161M, total assets $172M, total liabilities $32.8M, shareholders' equity $139M, long-term debt $19.9M
- Dec 31, 2024: cash $168M, total assets $178M, total liabilities $26.1M, shareholders' equity $151M, long-term debt $10.3M
- Sep 30, 2024: cash $182M, total assets $192M, total liabilities $26.6M, shareholders' equity $165M, long-term debt $6.63M
Is ANRO profitable?
No. ALTO NEUROSCIENCE INC lost $84.2M over the last four quarters.
What is ANRO's EPS?
Diluted earnings per share over the last four quarters were −$2.43; −$0.65 in the latest quarter.